Evolus expands Symatese partnership to commercialize Estyme HA gels in Canada, Australia, New Zealand

Reuters2026/08/04 12:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Evolus expanded its partnership with Symatese, securing exclusive rights to commercialize Estyme injectable hyaluronic acid gels in Canada, Australia, New Zealand.
Launch targeted for 2028, subject to regulatory approvals; adds dermal fillers alongside Nuceiva in those markets.
Neurotoxin and dermal filler markets in the three countries total about $500 million annually, split 60% neurotoxins, 40% fillers.
Symatese to handle development, manufacturing, clinical support, regulatory work; Evolus to pay an upfront fee, milestone payments, mid-single-digit royalty.
Terms include product purchases at a transfer price; deal expected to lift international gross margins using existing commercial infrastructure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608040830BIZWIRE_USPR_____20260804_BW612699) on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Evolus expands Symatese partnership to commercialize Estyme HA gels in Canada, Australia, New Zealand

You may also like

Crypto prices